Quantitative proteome analysis of overexpressed Cripto-1 tumor cell reveals 14-3-3γ as a novel biomarker in nasopharyngeal carcinoma

Journal of Proteomics

Volumn 83, Issue , 2013, Pages 26-36

  Wu, Zhengrong ^a   Weng, Desheng ^b   Li, Gang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Nasopharyngeal neoplasms; Proteomics; Tumor markers

Indexed keywords

14 3 3 GAMMA PROTEIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TUMOR CELL; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

14-3-3 PROTEINS; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876321362     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.03.001     Document Type: Article

References (40)

1. Jia W.H., Huang Q.H., Liao J., Ye W., Shugart Y.Y., Liu Q., et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 2006, 6:178.
2. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462.
3. Shao X., He Z., Chen Z., Yao K. Expression of an Epstein-Barr-virus receptor and Epstein-Barr-virus-dependent transformation of human nasopharyngeal epithelial cells. Int J Cancer 1997, 71:750-755.
4. Strizzi L., Bianco C., Normanno N., Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 2005, 24:5731-5741.
5. Wu Z., Li G., Wu L., Weng D., Li X., Yao K. Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma. BMC Cancer 2009, 9:315.
6. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006, 16:162-172.
7. Wang S., Li X., Li Z.G., Lu J., Fang W.Y., Ding Y.Q., et al. Gene expression profile changes and possible molecular subtypes in differentiated-type nonkeratinizing nasopharyngeal carcinoma. Int J Cancer 2011, 128:753-762.
8. Morrison D.K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009, 19:16-23.
9. Fan T., Li R., Todd N.W., Qiu Q., Fang H.B., Wang H., et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007, 67:7901-7906.
10. Jang J.S., Cho H.Y., Lee Y.J., Ha W.S., Kim H.W. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 2004, 14:491-499.
11. Lu J., Guo H., Treekitkarnmongkol W., Li P., Zhang J., Shi B., et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009, 16:195-207.
12. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Yu C.Y., et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005, 4:2062-2069.
13. Arora S., Matta A., Shukla N.K., Deo S.V., Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005, 42:97-108.
14. Qi W., Liu X., Qiao D., Martinez J.D. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer 2005, 113:359-363.
15. Wang Z., Nesland J.M., Suo Z., Trope C.G., Holm R. The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3beta and epsilon are independent prognostic factors for these tumors. PLoS One 2011, 6:e24843.
16. Brandt R., Normanno N., Gullick W.J., Lin J.H., Harkins R., Schneider D., et al. Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. J Biol Chem 1994, 269:17320-17328.
17. Normanno N., De Luca A., Bianco C., Maiello M.R., Carriero M.V., Rehman A., et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 2004, 198:31-39.
18. Sun Y., Strizzi L., Raafat A., Hirota M., Bianco C., Feigenbaum L., et al. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol 2005, 167:585-597.
19. Wechselberger C., Strizzi L., Kenney N., Hirota M., Sun Y., Ebert A., et al. Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene 2005, 24:4094-4105.
20. Van den Bergh G., Arckens L. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 2004, 15:38-43.
21. Friedman D.B., Hill S., Keller J.W., Merchant N.B., Levy S.E., Coffey R.J., et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4:793-811.
22. Rescher U., Gerke V. Annexins - unique membrane binding proteins with diverse functions. J Cell Sci 2004, 117:2631-2639.
23. Nagakubo D., Taira T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S.M., et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997, 231:509-513.
24. Bonifati V., Oostra B.A., Heutink P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J Mol Med (Berl) 2004, 82:163-174.
25. Kollermann J., Schlomm T., Bang H., Schwall G.P., von Eichel-Streiber C., Simon R., et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 2008, 54:1314-1323.
26. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011, 239:27-44.
27. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., Scholl S., et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7:3328-3335.
28. Pardo M., Garcia A., Thomas B., Pineiro A., Akoulitchev A., Dwek R.A., et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer 2006, 119:1014-1022.
29. Qi W., Liu X., Chen W., Li Q., Martinez J.D. Overexpression of 14-3-3gamma causes polyploidization in H322 lung cancer cells. Mol Carcinog 2007, 46:847-856.
30. Ajjappala B.S., Kim Y.S., Kim M.S., Lee M.Y., Lee K.Y., Ki H.Y., et al. 14-3-3Gamma is stimulated by IL-3 and promotes cell proliferation. J Immunol 2009, 182:1050-1060.
31. Sondak V.K., Gonzalez R.J., Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am 2011, 20:105-114.
32. Chan S.Y., To K.F., Leung S.F., Yip W.W., Mak M.K., Chung G.T., et al. 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma. Oncol Rep 2010, 24:949-955.
33. Yi B., Tan S.X., Tang C.E., Huang W.G., Cheng A.L., Li C., et al. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem 2009, 106:858-866.
34. Feng X.P., Yi H., Li M.Y., Li X.H., Yi B., Zhang P.F., et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010, 70:3450-3462.
35. Jiang P.Z., Gan M., Huang H., Shen X.M., Wang S., Yao K.T. Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells. Acta Biochim Biophys Sin (Shanghai) 2005, 37:97-106.
36. di Pietro A., Tosti G., Ferrucci P.F., Testori A. The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. Expert Opin Biol Ther 2011, 11:1395-1407.
37. Agarwala S.S., O'Day S.J. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat Rev 2011, 37:133-142.
38. Radhakrishnan V.M., Martinez J.D. 14-3-3Gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One 2010, 5:e11433.
39. Kannan S., De Santis M., Lohmeyer M., Riese D.J., Smith G.H., Hynes N., et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997, 272:3330-3335.
40. Ebert A.D., Wechselberger C., Frank S., Wallace-Jones B., Seno M., Martinez-Lacaci I., et al. Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res 1999, 59:4502-4505.